We are a clinical stage antibody drug conjugate company that has leveraged twenty years of industry learnings to develop proprietary technologies that enable us to design antibody drug conjugates with improved efficacy, safety and tolerability relative to existing ADC therapies. Our proprietary technologies combined with our deep understanding of target and patient selection allow us to create precisely targeted therapies with the potential to radically improve patient lives.
|Bank Name||Mersana Therapeutics, Inc.|
|Chairman||Ms. Anna Protopapas|
|CEO||Ms. Anna Protopapas|